MIRM Mirum Pharmaceuticals, Inc.
Q3 2025 10-Q
Mirum Pharmaceuticals, Inc. (MIRM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: EU HTA Regulation 2021/2282 effective Jan 12, 2025 may delay/refine pricing and reimbursement assessments impacting revenue in EU markets
- • Updated reimbursement risk: Elimination of Medicaid rebate cap effective Jan 1, 2024 increases rebate costs and compliance complexity under Medicaid Drug Rebate Program
Quarterly Financial SummaryXBRL
Revenue
$133M
▲ +47.2% YoY▲ +4.1% QoQ
Net Income
$3M
▲ +120.4% YoY▲ +149.6% QoQ
Operating Margin
2.0%
▲ +1599bp YoY▲ +586bp QoQ
Net Margin
2.2%
▲ +1793bp YoY▲ +677bp QoQ
ROE
1.0%
Total Assets
$785M
EPS (Diluted)
$0.07
▲ +123.3% YoY▲ +158.3% QoQ
Operating Cash Flow
$40M
▲ +896.0% YoY▲ +229.6% QoQ
Source: XBRL data from Mirum Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Mirum Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.